MalekiNChengYCTuY, et al.Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol2019; 85(6): 865–874.
3.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia2018; 38(1): 1–211.
4.
SantoroNBrownJRAdelT, et al.Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab1996; 81(4): 1495–1501.
5.
AegidiusKLZwartJAHagenK, et al.Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol2007; 14(1): 73–78.
6.
MisakianALLangerRDBensenorIM, et al.Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt)2003; 12(10): 1027–1036.
7.
NappiRECagnacciAGranellaF, et al.Course of primary headaches during hormone replacement therapy. Maturitas2001; 38(2): 157–163.
8.
FacchinettiFNappiRETirelliA, et al.Hormone supplementation differently affects migraine in postmenopausal women. Headache2002; 42(9): 924–929.
9.
SaccoSMerki-FeldGSKlAE, et al.Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain2018; 19(1): 76.
XiaoBLZhouLYZhangXL, et al.Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception1990; 41(4): 353–362.
12.
WatsonNRStuddJWRiddleAF, et al.Suppression of ovulation by transdermal oestradiol patches. BMJ1988; 297(6653): 900–901.
13.
VatankhahHKhaliliPVatanparastM, et al.Prevalence of early and late menopause and its determinants in Rafsanjan cohort study. Sci Rep2023; 13(1): 1847.
14.
VercelliniPViganoPSomiglianaE. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol2005; 17(4): 359–365.
